TABLE 1

Microdomain variants resulting in complete ablation of antibody bindinga

Peptide namebPeptide sequencecBoLA-DRβ3 haplotyping
SM.E6F7 Md-1GNGTGSSGSN
VP.E6F7-1.1GNGTDSSGSNH(*0601, *1001)(*0902, *1101)
VP.E6F7-1.3GNGTGS---N
SM.E6F7 Md-2KNTTDSTNNNG
VP.E6F7-2.5-NTADGNATTQR-(*0103, *0101)(*0101, *2703)(*0902, *1101)
VP.E6F7-2.7KN-TSGTAAQTNG
VP.E6F7-2.8KN-TAGTAAQTNG
VP.E6F7-2.10KN-TS-TAGATT
SM.G11 Md-1KGTGSTGSSGNK
VP.G11-1.5-GNG-TSG-GSTGT(*0601, *1001)(*0101, *2703)(*0902, *1101)
SM.StM1 Md-2VNATSGSTNNG
VP.StM1-2.2VN-T-GNTNNG(*0103, *0101)(*0601, *1001)(*0902, *1101)
VP.StM1-2.5VN-T-GNTNNNG
VP.StM1-2.6VN-T-G-TNNNG
VP.StM1-2.7VN-T-NTN--
VP.StM1-2.15VNAASGTTT---
  • a Variant peptides that resulted in complete ablation of antibody recognition, defined as binding that was statistically indistinguishable from that of preinfection serum in all biological replicates.

  • b Boldface indicates the parent St. Maries strain homologous peptide; VP indicates the specific variant peptide, as defined in Fig. 2 and 3.

  • c Italics indicate insertions relative to the parent St. Maries sequence, dashes indicate deletions, and underlining indicates substitutions.